Jan W. Eriksson

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

Bo Åhrén, Erik Simonsson, Hillevi Larsson et al. · Diabetes Care · 2002 · 423 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson et al. · Diabetologia · 2018 · 387 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen et al. · The Lancet Diabetes & Endocrinology · 2017 · 371 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 342 citations · Full text

Medicine, Nephrology, Pharmacology +13

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10